Gastric cancer is often diagnosed late, with limited prognosis and treatment options. The ONCOMICROBIOME project aims to identify tumor microbial signatures, understand their influence on tumor response, determine factors affecting prognosis and response to treatment, and test the clinical utility of these markers. Ultimately, it aims to enable more effective and personalised treatments.